No Data
No Data
Optimistic Investors Push BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shares Up 28% But Growth Is Lacking
Is There An Opportunity With BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 46% Undervaluation?
Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH): Its subsidiary Aiteme plans to carry out capital increase and share expansion.
GeLongHui, September 18th | brightgene bio-medical technology co.,ltd. (688166.SH) announced that, to support the development of the company's drug and device combination platform, meet the research and development and industrialization funding needs of products such as Etermei inhalation preparations, the controlling subsidiary Etermei plans to increase its capital. The total amount of this capital increase is 103 million yuan, of which Suzhou Hongbo Second Phase Investment Partnership Enterprise (Limited Partnership) (referred to as "Hongbo Second Phase") plans to subscribe to the newly increased registered capital of Etermei in the amount of 0.721397 million yuan in RMB for a price of 50 million yuan. Suzhou Dongwu Industrial M&A Guidance Fund Partnership Enterprise (Limited Partnership) (referred to as "Dongwu Fund").
BrightGene Bio-Medical Technology (SHSE:688166) Takes On Some Risk With Its Use Of Debt
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
No Data
No Data